Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6

Kimme Hyrich: 💉Risks of autoimmune flare is very low (3-5%) 💉Flares are mild when present after COVID-19 vaccination Most unvaccinated patients did NOT identify as "anti-vax"... number 1 reason is concerns about their health #EULAR2022 @RheumNow @rheum_covid https://t.co/Ogn0raifPd

Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr

#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj

#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC

Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52

Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT

Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/86e93ugoBQ

Pneumonia and influenza risk higher in patients with rheumatic disease! Influenza Relative Risk: 1.2-3.3 Pneumonia RR: shown to be up to 14.2 in SLE! 💉Vaccinations work! #EULAR2022 @Rheumnow @rheum_covid https://t.co/gvD1PaLQRe

Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD

Proof that vaccines work in our rheum patients; reduction in hospitalization, ICUs, death – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/u8PWvgfdiC

#EULAR2022: Kimme Hyrich: Think about Herpes zoster risk in ALL rheumatic disease patients (not just, but particularly with JAKs). 💉Avoid Zostavax (Live) in patients on immunosuppression 💉Warn side effects are common with Shingrix @RheumNow @rheum_covid https://t.co/w7p4oHuqL9

2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt

☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA: TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF *Association between BL IL-22 levels & W24 PASI75 and trend for BL IL-22 levels & W24 ACR20 #EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO

Dr. K Hyrich who/when to vaccinate. #EULAR2022 @rheumnow https://t.co/40y9ngJnbW